NuCanaNCNA
Market Cap: $7.66M
About: NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.
Employees: 28
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
14.67% less ownership
Funds ownership: 15.33% [Q1] → 0.66% (-14.67%) [Q2]
35% less funds holding
Funds holding: 23 [Q1] → 15 (-8) [Q2]
58% less capital invested
Capital invested by funds: $2.06M [Q1] → $867K (-$1.19M) [Q2]
67% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 12
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 11
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Oppenheimer Leland Gershell 55% 1-year accuracy 26 / 47 met price target | 633%upside $25 | Outperform Maintained | 3 Sept 2024 |
Oppenheimer Leland Gershell 55% 1-year accuracy 26 / 47 met price target | 4,299%upside $150 | Outperform Reiterated | 19 Aug 2024 |
Oppenheimer Leland Gershell 55% 1-year accuracy 26 / 47 met price target | 4,299%upside $150 | Outperform Reiterated | 23 Jul 2024 |
Oppenheimer Leland Gershell 55% 1-year accuracy 26 / 47 met price target | 4,299%upside $150 | Outperform Maintained | 22 Jul 2024 |
Financial journalist opinion
Based on 3 articles about NCNA published over the past 30 days